Funding
Series A · Biotech

CellsBin closes Series A led by 108 BioCapital

CellsBin closed a Series A led by 108 BioCapital in September, with the amount undisclosed.

Updated Oct 16, 2026By RoundOS Funding desk

The company plans faster commercialization, strategic partnerships, product development and expanded clinical and technical capabilities.

The round advances its rare-cell analysis platform, with initial applications in cell- and gene-therapy monitoring and hematologic cancers.

Use of funds

Accelerate commercialization and strategic partnerships

Develop products

Expand clinical and technical capabilities

Funding history

Series A · This roundUndisclosed

Sources

  1. CellsBin Closes Series A Financingfinsmes.com · Sep 22, 2026
  2. cellsbin.com

Similar rounds

All Biotech rounds →
Star Therapeutics

Biotechnology company discovering and developing antibody therapies for diseases with significant unmet need.

$200MPrivate financing · Oct 23, 2026
Pathos AI

Clinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.

$237MSeries E · Oct 23, 2026
Warp Sciences

Warp Sciences combines chemistry, AI and robotics to help drug discovery teams make and test molecules in the United States.

$215MSeries A · Oct 22, 2026
SEGNOS

SEGNOS develops magnetic-particle materials and diagnostic technologies for blood testing.

UndisclosedPre-Series A · Oct 22, 2026

Related